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Background
Following the success of the CAVD-VIMC ELISpot com-
parison study, the CAVD-VIMC ELISpot Assay Transfer
study was designed to evaluate the transfer of the ELISpot
assay SOP from IAVI CL to NVITAL using the same set of
150 samples. Assay results for the parent SOP (IAVI) from
the comparison study will be used to compare to those for
the transferred SOP (NVITAL). The co-primary objectives
are to ensure that the response rates are equivalent and the
positivity calls are concordant. Concordance of response
magnitudes among the dynamic range of positive
responders is evaluated in the secondary objectives.
Methods
To allow for resource-saving, a pre-specified interim anal-
ysis at n = 75 was designed for the study. Simulation stud-
ies incorporating past data demonstrated satisfactory
statistical power and justified the appropriate sample sizes
for both the interim and final analyses.
Results
The primary equivalence criteria on response rates and
positivity calls were both met in the interim analysis. The
95% C.I. on the difference in response rates is contained
in the pre-specified equivalence margin of [-15%, 15%]
(i.e. (-2.8%, 2.8%) for CMV and (-1.6%, 13.0%) for FEC
responses), and the lower bound of the 95% confidence
interval on the proportion of positivity concordance is
greater than the pre-specified margin of 70% (i.e. 94.7%
for CMV and 82.1% for FEC responses). Preliminary
investigation of the secondary objectives suggests that
Elispot readers are contributing to differences in raw spot
counts; concordance of response magnitudes improves
when plates from experiments performed at NVITAL were
read at IAVI. If accepted, both the interim and final study
results will be presented.
Conclusion
The transfer study continued to the testing of the remain-
ing samples. The interim analysis allowed for an early
look of futility and helped to identify sources of any pos-
sible differences between the parent and the transferred
SOP.
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